Sanofi is to buy Principia Biopharma for up to $3.68 billion ... give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty ...
One of the main assets of Sanofi's $3.7 billion buyout of Principia Biopharma has run ... phase 3 trials of the BTK inhibitor tolebrutinib (SAR442168) in multiple sclerosis and myasthenia gravis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback